Compare STRIDES PHARMA SCIENCE with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs DIVIS LABORATORIES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE DIVIS LABORATORIES STRIDES PHARMA SCIENCE/
DIVIS LABORATORIES
 
P/E (TTM) x 14.8 32.6 45.4% View Chart
P/BV x 0.9 7.4 11.9% View Chart
Dividend Yield % 0.6 0.6 91.1%  

Financials

 STRIDES PHARMA SCIENCE   DIVIS LABORATORIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
DIVIS LABORATORIES
Mar-18
STRIDES PHARMA SCIENCE/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1471,142 100.5%   
Low Rs642533 120.4%   
Sales per share (Unadj.) Rs317.2146.6 216.4%  
Earnings per share (Unadj.) Rs7.833.0 23.7%  
Cash flow per share (Unadj.) Rs25.138.4 65.2%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.2 18.7%  
Book value per share (Unadj.) Rs274.3222.8 123.1%  
Shares outstanding (eoy) m89.50265.47 33.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.85.7 49.4%   
Avg P/E ratio x114.025.3 449.8%  
P/CF ratio (eoy) x35.721.8 163.7%  
Price / Book Value ratio x3.33.8 86.8%  
Dividend payout %25.530.3 84.2%   
Avg Mkt Cap Rs m80,058222,318 36.0%   
No. of employees `0002.510.8 23.3%   
Total wages/salary Rs m4,3414,561 95.2%   
Avg. sales/employee Rs Th11,325.83,616.0 313.2%   
Avg. wages/employee Rs Th1,731.4423.8 408.6%   
Avg. net profit/employee Rs Th280.1814.9 34.4%   
INCOME DATA
Net Sales Rs m28,39438,915 73.0%  
Other income Rs m9411,134 82.9%   
Total revenues Rs m29,33440,049 73.2%   
Gross profit Rs m3,96512,617 31.4%  
Depreciation Rs m1,5401,425 108.1%   
Interest Rs m1,96213 14,754.9%   
Profit before tax Rs m1,40312,313 11.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m973,543 2.7%   
Profit after tax Rs m7028,770 8.0%  
Gross profit margin %14.032.4 43.1%  
Effective tax rate %6.928.8 24.1%   
Net profit margin %2.522.5 11.0%  
BALANCE SHEET DATA
Current assets Rs m24,83645,351 54.8%   
Current liabilities Rs m18,9936,507 291.9%   
Net working cap to sales %20.699.8 20.6%  
Current ratio x1.37.0 18.8%  
Inventory Days Days71127 56.0%  
Debtors Days Days11395 119.2%  
Net fixed assets Rs m34,28921,160 162.0%   
Share capital Rs m895531 168.6%   
"Free" reserves Rs m23,65158,625 40.3%   
Net worth Rs m24,54659,156 41.5%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43767,832 96.5%  
Interest coverage x1.7926.8 0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 75.6%   
Return on assets %4.112.9 31.4%  
Return on equity %2.914.8 19.3%  
Return on capital %6.920.8 33.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m15,69732,359 48.5%   
Fx outflow Rs m7359,042 8.1%   
Net fx Rs m14,96223,317 64.2%   
CASH FLOW
From Operations Rs m1,8717,759 24.1%  
From Investments Rs m5,826-4,783 -121.8%  
From Financial Activity Rs m-10,157-3,142 323.3%  
Net Cashflow Rs m-2,615-166 1,575.2%  

Share Holding

Indian Promoters % 27.7 52.0 53.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.8 320.3%  
FIIs % 8.6 19.0 45.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.2 150.6%  
Shareholders   56,241 31,796 176.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS